Industry News
Pharmaceutical Industry News
Pitted against the…
Pitted against the immunosuppressant mycophenolate mofetil, Roche’s CD20-targeting antibody Gazyva helped more kids and young adults with idiopathic nephrotic syndrome achieve sustained remission after one year, according to a topline readout from the Swiss drugmaker’s
Citing insurance claims data,…
Citing insurance claims data, CSL’s leaders said they expect this season's flu vaccination rates in the U.S. to decline by 12% overall and by 14% for people ages 65 and older compared with last year.
The FDA slammed generics maker…
The FDA slammed generics maker Hetero with a Form 483 after an inspection of one of its warehouses in India uncovered flying birds, skittering lizards and roaming cats, among a host of other infractions.
In Lilly’s new awareness campaign,…
In Lilly's new awareness campaign, the NBA legend shares his sleep apnea story and encourages others to discuss their symptoms with a doctor.
CDMO Catalent has unveiled a new…
CDMO Catalent has unveiled a new corporate brand, which keeps the company’s moniker the same while trading in the simple blue-against-white lettering of its previous logo with a pair of intersecting, speech bubble-like boxes bearing
Cigna’s Evernorth division is…
Cigna's Evernorth division is rolling out a rebate-free model for its pharmacy benefit manager, Express Scripts—meaning one of the industry's "Big Three" is moving away from the oft-criticized approach.
Innovent’s Eli Lilly-partnered…
Innovent's Eli Lilly-partnered mazdutide, a GLP-1/glucagon (GCG) dual receptor agonist, displayed broader effects on patients' blood glucose levels and weight loss than Novo's leading GLP-1 semaglutide in a head-to-head trial.
Paving the way for the label…
Paving the way for the label update were results from the phase 3 Zenith trial, which was stopped early due to a positive efficacy signal.
AstraZeneca and Organon have been…
AstraZeneca and Organon have been found in serious breach of the U.K.’s pharma code, with a watchdog ruling that both companies brought discredit on the industry.
Organon’s chief executive Kevin…
Organon’s chief executive Kevin Ali—who had been with the company since its 2021 debut—resigned from his role and exited the company’s board of directors Sunday, Organon said in a securities filing. The company’s EVP and
La testosterona devuelve a las mujeres su deseo sexual, pero hay algo más
No existe ningún producto de testosterona para mujeres aprobado por la FDA. Los seguros no la cubren y muchos médicos no la recetan. Aun así, se ha convertido en todo un fenómeno cultural.
FDA Approves New Menopause Drug to Treat Hot Flashes and Night Sweats
The drug, one of the few nonhormonal options for menopausal women, reduced hot flashes and night sweats, and appears to help with sleep issues.
Following a slight delay earlier…
Following a slight delay earlier this year—and a world-first green light in the U.K. over the summer—Bayer has clinched an FDA nod to bolster the limited arsenal of nonhormonal treatments for one of the most
Ipsen unveiled a new educational…
Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their pediatricians to adult care, for which they’re often unprepared.
Over the last 13 months, Sanofi…
Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. On Friday, Sanofi reported that Dupixent achieved a new standard as quarterly
A cystic fibrosis buyers group has…
A cystic fibrosis buyers group has resurfaced in a bid to improve access to Vertex's expensive combination therapy Trikafta. Under the strategy, a much cheaper copycat of the modulator drug is slated to launch next
Last year, Japan’s Renalys picked…
Last year, Japan's Renalys picked up certain Asian rights to the IgAN medicine sparsentan from the medicine's developer, Travere Therapeutics. Chugai is set to take the medicine forward in the licensed countries under a new
After a negative advisory…
After a negative advisory committee vote and a postponed approval decision, the FDA opted to approve GSK's Blenrep in one of its two proposed combinations.
The company expects sales in the…
The company expects sales in the second half of the year to outpace those from the first and reiterated its annual revenue guidance, projecting growth between 20% and 21% for all of 2025.
To reach the target audience of…
To reach the target audience of geographic atrophy (GA) treatment Izervay, Astellas Pharma has turned to the “internet’s grandma,” cookbook author and popular social media creator Barbara “Babs” Costello.